Ginsenoside Rg1 Decreases Aβ1-42 Level by Upregulating PPARγ and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Quan, QianKun ^a   Wang, Jue ^a   Li, Xi ^b   Wang, Yi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; EOSIN; GINSENOSIDE RG 1; HEMATOXYLIN; INSULINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MALE; MEMORY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPATIAL LEARNING; UPREGULATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILIDES; ANIMALS; CA1 REGION, HIPPOCAMPAL; CENTRAL NERVOUS SYSTEM AGENTS; GENE EXPRESSION REGULATION; GINSENOSIDES; INSULYSIN; LEARNING; MALE; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84874786893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059155     Document Type: Article

References (52)

1. Luo DZ, Hou XY, Hou L, Wang MX, Xu S, et al. (2011) Effect of pioglitazone on altered expression of A beta metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance. European Journal of Pharmacology 664: 14-19.
2. Tanzi RE, Moir RD, Wagner SL, (2004) Clearance of Alzheimer's A beta peptide: The many roads to perdition. Neuron 43: 605-608.
3. Kurochkin IV, (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends in Biochemical Sciences 26: 421-425.
4. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, et al. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proceedings of the National Academy of Sciences of the United States of America 100: 4162-4167.
5. Fernandez-Gamba A, Leal MC, Morelli L, Castano EM, (2009) Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease. Current Pharmaceutical Design 15: 3644-3655.
6. Dorfman VB, Pasquini L, Riudavets M, Lopez-Costa JJ, Villegas A, et al. (2010) Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiology of Aging 31: 1743-1757.
7. Miners JS, Baig S, Tayler H, Kehoe PG, Love S, (2009) Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity. Journal of Neuropathology and Experimental Neurology 68: 902-914.
8. Bulloj A, Leal MC, Xu HX, Castano EM, Morelli L, (2010) Insulin-Degrading Enzyme Sorting in Exosomes: A Secretory Pathway for a Key Brain Amyloid-beta Degrading Protease. J Alzheimer's Dis 19: 79-95.
9. Attele AS, Wu JA, Yuan CS, (1999) Ginseng pharmacology-Multiple constituents and multiple actions. Biochemical Pharmacology 58: 1685-1693.
10. Fang F, Chen X, Huang T, Lue LF, Luddy JS, et al. (2012) Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochimica et Biophysica Acta 1822: 286-292.
11. Wang YH, Du GH, (2009) Ginsenoside Rg1 inhibits beta-secretase activity in vitro and protects against A beta-induced cytotoxicity in PC12 cells. Journal of Asian Natural Products Research 11: 604-612.
12. Mook-Jung I, Hong HS, Boo JH, Lee KH, Yun SH, et al. (2001) Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. Journal of Neuroscience Research 63: 509-515.
13. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, et al. (2010) Ginsenoside Rg1 Attenuates Amyloid-beta Content, Regulates PKA/CREB Activity, and Improves Cognitive Performance in SAMP8 Mice. Journal of Alzheimers Disease 19: 977-989.
14. Gong L, Li SL, Li H, Zhang L, (2011) Ginsenoside Rg1 protects primary cultured rat hippocampal neurons from cell apoptosis induced by beta beta-amyloid protein. Pharmaceutical Biology 49: 501-507.
15. Liu QA, Kou JP, Yu BY, (2011) Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kappa B activation. Neurochemistry International 58: 119-125.
16. Chen YB, Zhang DP, Feng M, Wang Q, Cheng SY, et al. (2009) Effects of Ginsenoside Rg1 on nuclear factor-kappa B activity in beta amyloid protein-treated neural cells. Neural Regeneration Research 4: 590-596.
17. Cheng Y, Shen LH, Zhang JT, (2005) Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacologica Sinica 26: 143-149.
18. Ni HX, Yu NJ, Yang XH, (2010) The study of ginsenoside on PPAR gamma expression of mononuclear macrophage in type 2 diabetes. Molecular Biology Reports 37: 2975-2979.
19. Du J, Zhang L, Liu SB, Zhang C, Huang XQ, et al. (2009) PPAR gamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons. Biochemical and Biophysical Research Communications 383: 485-490.
20. Zhou J, Zhou L, Hou DR, Tang JC, Sun JJ, et al. (2011) Paeonol increases levels of cortical cytochrome oxidase and vascular actin and improves behavior in a rat model of Alzheimer's disease. Brain Research 1388: 141-147.
21. Bagheri M, Joghataei MT, Mohseni S, Roghani M, (2011) Genistein ameliorates learning and memory deficits in amyloid beta((1-40)) rat model of Alzheimer's disease. Neurobiology of Learning and Memory 95: 270-276.
22. Yamaguchi Y, Higashi M, Kobayashi H, (1997) Effects of ginsenosides on maze performance and brain choline acetyltransferase activity in scopolamine-treated young rats and aged rats. European Journal of Pharmacology 329: 37-41.
23. Goyal SN, Bharti S, Bhatia J, Nag TC, Ray R, et al. (2011) Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obesity & Metabolism 13: 533-541.
24. Kumar A, Seghal N, Naidu PS, Padi SSV, Goyal R, (2007) Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacological Reports 59: 274-283.
25. Wang YJ, Gao CY, Yang MA, Liu XH, Sun Y, et al. (2010) Intramuscular delivery of a single chain antibody gene prevents brain A beta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behavior and Immunity 24: 1281-1293.
26. Rosi S, Pert CB, Ruff MR, McGann-Gramling K, Wenk GL, (2005) Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. Neuroscience 134: 671-676.
27. Watson GS, Craft S, (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease-Implications for treatment. Cns Drugs 17: 27-45.
28. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, de Maturana RL, et al. (2010) Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology. Neuropsychopharmacology 35: 1593-1604.
29. Logroscino G, Kang JH, Grodstein F, (2004) Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. British Medical Journal 328: 548-551.
30. Peila R, Rodriguez BL, White LR, Launer LJ, (2004) Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63: 228-233.
31. Gispen WH, Biessels GJ, (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences 23: 542-549.
32. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, et al. (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Research 888: 256-262.
33. Qiu WQ, Folstein MF, (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiology of Aging 27: 190-198.
34. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, et al. (2003) Insulin increases CSF A beta 42 levels in normal older adults. Neurology 60: 1899-1903.
35. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, et al. (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon 4 allele. American Journal of Pathology 162: 313-319.
36. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M, (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obesity & Metabolism 12: 716-721.
37. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes-An interim analysis. New England Journal of Medicine 357: 28-38.
38. Wang AT, Smith SA (2010) In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone. Annals of Internal Medicine 153.
39. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, et al. (2011) Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study. Diabetes Care 34: 916-922.
40. Zhao Z, Xiang ZM, Haroutunian V, Buxbaum JD, Stetka B, et al. (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiology of Aging 28: 824-830.
41. Perez A, Morelli L, Cresto JC, Castano EM, (2000) Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochemical Research 25: 247-255.
42. Vepsalainen S, Hiltunen M, Helisalmi S, Wang J, van Groen T, et al. (2008) Increased expression of A beta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neuroscience Letters 438: 216-220.
43. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, et al. (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. Journal of Biological Chemistry 276: 21895-21901.
44. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, et al. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. Journal of Neuroscience 23: 1992-1996.
45. Eckman EA, Reed DK, Eckman CB, (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. Journal of Biological Chemistry 276: 24540-24548.
46. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB, (2003) Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. Journal of Biological Chemistry 278: 2081-2084.
47. Hu JG, Igarashi A, Kamata M, Nakagawa H, (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); Retards A beta aggregation, deposition, fibril formation, and inhibits cytotoxicity. Journal of Biological Chemistry 276: 47863-47868.
48. Van Nostrand WE, Porter M, (1999) Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38: 11570-11576.
49. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, et al. (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. Journal of Neuroscience 20: 3937-3946.
50. Yan P, Hu XY, Song HW, Yin KJ, Bateman RJ, et al. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. Journal of Biological Chemistry 281: 24566-24574.
51. Deane R, Bell RD, Sagare A, Zlokovic BV, (2009) Clearance of Amyloid-beta Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimer's Disease. Cns & Neurological Disorders-Drug Targets 8: 16-30.
52. Zlokovic BV, (2004) Clearing amyloid through the blood-brain barrier. Journal of Neurochemistry 89: 807-811.